Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Colorcon
Boehringer Ingelheim
Mallinckrodt
Merck

Last Updated: December 6, 2019

DrugPatentWatch Database Preview

RIVASTIGMINE TARTRATE Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Rivastigmine Tartrate patents expire, and what generic alternatives are available?

Rivastigmine Tartrate is a drug marketed by Alembic Pharms Ltd, Apotex Inc, Aurobindo Pharma Ltd, Cadila Pharms Ltd, Chartwell Rx, Dr Reddys Labs Inc, Macleods Pharms Ltd, Orchid Hlthcare, Sun Pharm, and Watson Labs. and is included in ten NDAs.

The generic ingredient in RIVASTIGMINE TARTRATE is rivastigmine tartrate. There are thirty-two drug master file entries for this compound. Fourteen suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the rivastigmine tartrate profile page.

Drug patent expirations by year for RIVASTIGMINE TARTRATE
Drug Prices for RIVASTIGMINE TARTRATE

See drug prices for RIVASTIGMINE TARTRATE

Recent Clinical Trials for RIVASTIGMINE TARTRATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Duke UniversityPhase 1/Phase 2
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.Phase 1/Phase 2
Taishoff Family FoundationPhase 1/Phase 2

See all RIVASTIGMINE TARTRATE clinical trials

Recent Litigation for RIVASTIGMINE TARTRATE

Identify potential future generic entrants

District Court Litigation
Case NameDate
Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc.2013-08-22
Novartis Pharmaceuticals Corporation v. Noven Pharmaceuticals Inc.2013-04-03
Novartis Pharmaceuticals Corporation v. Watson Laboratories, Inc.2011-11-10

See all RIVASTIGMINE TARTRATE litigation

Pharmacology for RIVASTIGMINE TARTRATE
Paragraph IV (Patent) Challenges for RIVASTIGMINE TARTRATE
Tradename Dosage Ingredient NDA Submissiondate
EXELON SOLUTION;ORAL rivastigmine tartrate 021025 2004-11-05
EXELON CAPSULE;ORAL rivastigmine tartrate 020823 2004-04-21

US Patents and Regulatory Information for RIVASTIGMINE TARTRATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Orchid Hlthcare RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 090879-004 Jun 10, 2015 AB RX No No   Start Trial   Start Trial   Start Trial
Macleods Pharms Ltd RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 203148-004 Aug 22, 2014 AB RX No No   Start Trial   Start Trial   Start Trial
Sun Pharm RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 077131-001 Oct 22, 2007 AB RX No No   Start Trial   Start Trial   Start Trial
Orchid Hlthcare RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 090879-001 Jun 10, 2015 AB RX No No   Start Trial   Start Trial   Start Trial
Alembic Pharms Ltd RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 091689-001 Jun 12, 2012 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
McKinsey
Medtronic
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.